{"id":"390827bfbfcd","type":"article","url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","title":"Aanhoudende LDL-verlaging met alirocumab in ODYSSEY OUTCOMES","title_en":"Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","lipide-aferese","lipidenverlaging"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2019.11.030","source_url":"https://doi.org/10.1016/j.jacc.2019.11.030","authors":["Shaun G Goodman","Philippe Gabriel Steg","Michael Szarek","Deepak L Bhatt","Vera A Bittner","Rafael Diaz","Robert A Harrington","J Wouter Jukema","Harvey D White","Andreas M Zeiher","Gregory G Schwartz"],"significance":6,"published":"2020-02-04","source_date":"2020-02-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"This ODYSSEY OUTCOMES analysis demonstrated sustained LDL cholesterol lowering with alirocumab over the full trial duration, confirming durable PCSK9 inhibitor efficacy without treatment-emergent resistance.","created":"2026-07-03T10:28:25Z","updated":"2026-07-03T13:27:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ODYSSEY OUTCOMES analyse naar de duurzaamheid van LDL-verlaging met alirocumab over de langere termijn.","abstract_original":""}